Meeting
2018 ASCO Annual Meeting
A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
Authors
Sosana Delimpasi
General Hospital of Athens, Athens, Greece
Sosana Delimpasi , Ludek Pour , Holger W Auner , Meletios A. Dimopoulos , Alon Rappaport , Lisa Fortin , Jatin J. Shah , Sharon Shacham , Michael G. Kauffman , Nizar J. Bahlis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03110562
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS8056)
DOI
10.1200/JCO.2018.36.15_suppl.TPS8056
Abstract #
TPS8056
Poster Bd #
64b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2018 ASCO Annual Meeting
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
First Author: Pieter Sonneveld
First Author: Andrew Spencer
Poster
2020 ASCO Virtual Scientific Program
Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto